logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 20 of 68 Items
Showing 1 - 20 of 68 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Commentary

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa

Chu WY, Verrest L, Younis BM, Musa AM, Mbui J,  et al.
2024-12-16 • Journal of Infectious Diseases
2024-12-16 • Journal of Infectious Diseases

Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to...

Technical Report
|
Evidence Brief

A war on people: the human cost of conflict and violence in Sudan

MSF (Médecins Sans Frontières)
2024-07-22
2024-07-22

The consequences of over a year of full-blown conflict on the health and wellbeing of people in Sudan are disastrous. The population has faced horrendous levels of violence, succumbin...

Conference Material
|
Video

High mortality and violence among refugees and returnees from West Darfur, Sudan arriving in Chad, 2023: results from three retrospective mortality surveys

Simons E
2024-07-01 • Epicentre Scientific Day 2024
2024-07-01 • Epicentre Scientific Day 2024
Conference Material
|
Poster

Enquête de mortalité, de prévalence nutritionnelle et de couverture vaccinale rougeole sur 3 camps de réfugiés soudanais et de retournés tchadiens à l’est du Tchad

Ouedraogo P, Simons E, Grellety E
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024
Conference Material
|
Abstract

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Treatment options for the highly neglected fungal tropical disease eumycetoma are limited and poorly adapted to patients’ contexts, with surgery often required. The firs...
Conference Material
|
Video

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Slide Presentation

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Journal Article
|
Letter

Al-Buluk children's hospital in Khartoum

Eltahir E, Abdelhafiz K, Ali M, Abdelgalil S, Thomas E
2024-03-16 • Lancet
2024-03-16 • Lancet
Journal Article
|
Commentary

An oral antiviral for Ebola disease

Sprecher A, Van Herp M
2024-03-15 • Science
2024-03-15 • Science
For those exposed to filovirus, such as Sudan virus and Ebola virus, a new study offers hope.
Journal Article
|
Review

Antimicrobial resistance in Enterobacterales infections among children in sub-Saharan Africa: a systematic review and meta-analysis

Kowalski M, Minka Obama B, Catho G, Dewez JE, Merglen A,  et al.
2024-03-08 • eClinicalMedicine
2024-03-08 • eClinicalMedicine
BACKGROUND
The burden of antimicrobial resistance (AMR) has been estimated to be the highest in sub-Saharan Africa (SSA). The current study estimated the proportion of drug-resistant...
Journal Article
|
Commentary

Benefiting some more than others: humanitarian disruption in conflict settings

L’Homme M
2023-11-23 • Journal of Humanitarian Affairs
2023-11-23 • Journal of Humanitarian Affairs
In March 2022, intercommunal fighting forced Médecins Sans Frontières (MSF) to suspend its activities after nearly fourteen years of operating in Agok, a small town located in the disput...
Journal Article
|
Research

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga SN,  et al.
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
Journal Article
|
Research

Host preference and human blood index of Phlebotomus orientalis, an exophilic sand fly vector of visceral leishmaniasis in eastern Sudan

Jibreel T, Khogali A, Jiménez M, Raiyed A, Dakein O,  et al.
2023-08-04 • Medical and Veterinary Entomology
2023-08-04 • Medical and Veterinary Entomology
Visceral leishmaniasis (VL, kala azar), caused by Leishmania donovani, transmitted by Phlebotomus orientalis, is a serious systemic disease that causes high morbidity and mortality rates...
Conference Material
|
Slide Presentation

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...
Conference Material
|
Video

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|
Research

Prognostic value of different anthropometric indices over different measurement intervals to predict mortality in 6–59-month-old children

Briend A, Myatt M, Berkley JA, Black RE, Boyd EM,  et al.
2023-06-01 • Public Health Nutrition
2023-06-01 • Public Health Nutrition
OBJECTIVE
To compare the prognostic value of mid-upper arm circumference (MUAC), weight-for-height Z-score (WHZ) and weight-for-age Z-score (WAZ) for predicting death over periods of...
Journal Article
|
Commentary

Implementation of community-based management of severe acute malnutrition in conflict affected regions: a case of South Kordofan, Sudan

Sserwanja Q, Adam OO, Mohamed EH, Adam MB, Mutisya LM
2023-03-29 • Archives of Public Health
2023-03-29 • Archives of Public Health
Malnutrition is the major cause of mortality and morbidity globally with undernutrition contributing about 45% of all deaths of under five children. Besides the direct effects of protrac...
Journal Article
|
Research

Anthropometric criteria for best-identifying children at high risk of mortality: a pooled analysis of twelve cohorts

Khara T, Myatt M, Sadler K, Bahwere P, Berkley JA,  et al.
2023-02-03 • Public Health Nutrition
2023-02-03 • Public Health Nutrition
OBJECTIVE
To understand which anthropometric diagnostic criteria best discriminate higher from lower risk of death in children and explore programme implications.

DESIGN
Journal Article
|
Letter

Hepatitis E virus outbreak among Tigray War refugees from Ethopia, Sudan

Azman AS, Gignoux E, Nesbitt R, Rumunu J, Aggarwal R,  et al.
2023-02-01 • Emerging Infectious Diseases
2023-02-01 • Emerging Infectious Diseases